Oral Ferric Citrate Hydrate Associated With Less Oxidative Stress Than Intravenous Saccharated Ferric Oxide.
Oral Ferric Citrate Hydrate Associated With Less Oxidative Stress Than Intravenous Saccharated Ferric Oxide.
复制标题
DOI：
10.1016/j.ekir.2017.10.016
复制
发表时间：
2018-03
影响因子：
6
通讯作者：
Hirakata H
中科院分区：
文献类型：
--
作者：
Nakayama M;Tani Y;Zhu WJ;Watanabe K;Yokoyama K;Fukagawa M;Akiba T;Wolf M;Hirakata H
最近的一项研究表明，口服柠檬酸铁水合物 (FC) 可纠正血液透析 (HD) 患者的肾性贫血，这表明不同给药途径补铁效果存在生物学差异。为了解决这个问题，本研究比较了口服 FC 和静脉注射。稳定 HD 患者中的糖化氧化铁 (FO)。参与者包括 6 名患者，在本周的第一次 HD 疗程中，在禁食状态下接受了 3 个连续方案：不给予任何药物，作为对照 (C)；口服 FC（480 毫克铁），静脉注射 5 分钟。 FO（40 毫克铁）。检查了研究期间（6 小时）体内铁的动态以及对氧化还原炎症状态的生物学影响。 FC 和 FO 均观察到血清铁和转铁蛋白饱和度显着增加。将总铁结合力作为血清铁和不饱和铁结合力的总和，FC 中没有发现变化，而 FO 中观察到显着增加（非转铁蛋白结合铁 [NTBI] 的出现），尽管 FO 中的血清铁水平较低。与C相比，FO中血清髓过氧化物酶（氧化标记物）增加，硫氧还蛋白（抗氧化剂）显着降低，而FC中没有发现变化。口服 FC 与静脉注射不同。 FO 的领域包括减少 NTBI 生成和减少氧化应激诱导。结果表明，口服 FC 对于 HD 患者肾性贫血补铁具有潜在的临床益处。
A recent study suggested that orally dosed ferric citrate hydrate (FC) corrects renal anemia in patients on hemodialysis (HD), suggesting biological differences in effects of iron supplementation using different routes of administration. To address this issue, the present study compared oral FC with i.v. saccharated ferric oxide (FO) in stable HD patients. Participants comprised 6 patients administered 3 consecutive protocols in the first HD session of the week in a fasting state: nothing given, as control (C); oral load of FC (480 mg iron), and 5 minutes of i.v. FO (40 mg iron). Iron dynamics in the body and biological impact on redox-inflammation status during the study (6 hours) were examined. Significant increases in serum iron and transferrin saturation were seen with both FC and FO. Regarding total iron-binding capacity as the sum of serum iron and unsaturated iron-binding capacity, no changes were found in FC, whereas significant increases were seen in FO (appearance of non–transferrin-binding iron [NTBI]), despite the lower serum iron levels in FO. Compared with C, increases were seen in serum myeloperoxidase (oxidative marker) with accompanying significant decreases in thioredoxin (antioxidant) in FO, whereas no changes were found in FC. Oral FC differs from i.v. FO in areas such as less NTBI generation and less induction of oxidative stress. The result indicates potential clinical benefits of oral FC in terms of iron supplementation for renal anemia in HD patients.
登录
查看更多内容
影响因子：
13.6
作者：
Babitt, Jodie L.;Lin, Herbert Y.
通讯作者：
Lin, Herbert Y.
影响因子：
11.5
作者：
Rostoker, Guy;Vaziri, Nosratola D.;Fishbane, Steven
通讯作者：
Fishbane, Steven
影响因子：
4.2
作者：
Yokoyama, Keitaro;Hirakata, Hideki;Kumagai, Yuji
通讯作者：
Kumagai, Yuji
影响因子：
6.1
作者：
Zanen, AL;Adriaansen, HJ;deJong, GMT
通讯作者：
deJong, GMT
DOI：
10.2215/cjn.01420406
发表时间：
2006-09-01
影响因子：
9.8
作者：
Bishu, Kalkidan;Agarwal, Rajiv
通讯作者：
Agarwal, Rajiv